MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ
3.170
+0.200
+6.73%
After Hours: 3.150 -0.02 -0.63% 17:30 03/01 EST
OPEN
3.180
PREV CLOSE
2.970
HIGH
3.330
LOW
3.000
VOLUME
93.83K
TURNOVER
0
52 WEEK HIGH
20.66
52 WEEK LOW
1.490
MARKET CAP
13.75M
P/E (TTM)
-0.2534
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at HEPA last week (0219-0223)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Autonomix Medical (NASDAQ:AMIX) stock rose 30.3% to $4.95 during Monday's pre-market session. Sarepta Therapeutics stock increased by 12.64% to $140.68. The company's market cap stands at $13.1 billion.
Benzinga · 02/19 13:05
Weekly Report: what happened at HEPA last week (0212-0216)?
Weekly Report · 02/19 10:34
Hepion Pharmaceuticals Bolsters Capital with Equity Deals
TipRanks · 02/16 14:12
Hepion announces exercise of warrants for about $2M gross proceeds
Seeking Alpha · 02/16 13:35
SPWR, BREA and HEPA among pre-market losers
On the Move SPWR, BREA and HEPA among pre-market losers. Trupanion TRUP -24% after Q4 earnings release. Bloom Energy Corp BE -19% reports Q4 results. Jan. One, chanson international and yelp among other companies to report results.
Seeking Alpha · 02/16 13:27
12 Health Care Stocks Moving In Friday's Pre-Market Session
China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. Sarepta Therapeutics shares moved upwards by 14.5%. MediciNova stock rose by 17.77% as the company's Q4 earnings report came out yesterday. Losers Inventiva and T2 Biosystems also lost ground.
Benzinga · 02/16 13:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Sientra stock rose 193.5% to $0.53 during Thursday's regular session. Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 28.78%. American Well (NYSE:AMWL) shares rose 18.91%. Renalytix stock decreased by 32.2% during the session.
Benzinga · 02/15 17:31
More
About HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

Webull offers Hepion Pharmaceuticals Inc stock information, including NASDAQ: HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.